Proven safety and efficacy

The therapeutic efficacy and safety of platelets treated with the INTERCEPT™ Blood System has been demonstrated in 10 randomised clinical trials.

The three main INTERCEPT studies proving equivalence to conventional platelets are:  

1. The SPRINT trial – Apheresis platelets: The primary endpoint was the proportion of patients with grade 2 bleeding (as adapted from World Health Organization (WHO) bleeding scale). A total of 645 patients were evaluated.
2. The EuroSPRITE trial – Pooled buffy coat platelets: The primary endpoint was the mean 1-hour corrected count increment. A total of 52 patients were evaluated in the test group.
3. The TESSI trial – Apheresis platelets stored for 6-7 days: The primary end point was the mean 1-hour corrected count increment. A total of 101 patients were evaluated in the test group.

When transfusing INTERCEPT-treated platelet concentrates, you know that safety and efficacy have been demonstrated in multiple randomised, double-blind clinical trials.